论文部分内容阅读
目的观察低分子肝素钙联合疏血通治疗不稳定心绞痛的临床疗效及安全性。方法80例不稳定心绞痛患者随机分成两组,治疗组(40例)在常规治疗心绞痛的基础上应用低分子肝素钙联合疏血通治疗,两周后两组进行心绞痛症状、心电图ST段、血脂,对比观察;治疗组进行用药前后血液流变学对比观察。结果治疗组症状疗效总有效率为95%,心电图改善率为91.7%,优于对照组的75%和72.2%,与对照组相比差异具有统计学意义(P<0.05),治疗组治疗前后血脂下降显著(P<0.01),对照组血脂改变无统计学意义(P>0.05);治疗组较治疗前出凝血指标都延长,但无临床出血等并发症。结论低分子肝素钙联合疏血通治疗不稳定心绞痛优于常规治疗,且安全性高。
Objective To observe the clinical efficacy and safety of low molecular weight heparin combined with Shuxuetong in the treatment of unstable angina pectoris. Methods Eighty patients with unstable angina were randomly divided into two groups. The treatment group (40 cases) was treated with low molecular weight heparin combined with Shuxuetong on the basis of routine angina pectoris. Two weeks later, angina pectoris, ST segment of electrocardiogram, , Comparative observation; treatment group before and after treatment of hemorheology comparative observation. Results The total effective rate of the treatment group was 95%, the improvement rate of electrocardiogram was 91.7%, which was better than that of the control group (75% and 72.2%), the difference was statistically significant compared with the control group (P <0.05) There was no significant difference in the blood lipids in the control group (P> 0.05). The coagulation index in the treatment group was prolonged before treatment, but no complications such as clinical bleeding were found. Conclusion Low molecular weight heparin combined with Shuxuetong is superior to conventional treatment in treating unstable angina and is safe.